Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase CK2al-rs]
Substrate: SNCA

Description: Alpha-synuclein (Non-A beta component of AD amyloid) (Non-A4 componentof amyloid precursor) (NACP).

Synonyms: NACP, PARK1

Ensembl ID: ENSG00000145335

UniprotKB/SwissProt: SYUA_HUMAN (P37840)

Function: May be involved in the regulation of dopamine release and transport. Soluble protein, normally localized primarily at the presynaptic region of axons, which can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies). Induces fibrillization of microtubule- associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation.

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Cytoplasm. Membrane. Nucleus. Note=Membrane- bound in dopaminergic neurons. Also found in the nucleus.
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of SNCA

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1SNCASYUA_HUMANS9FMKGL S KAKEG 38.96%GPRK6 HPRD:01227(in vitro)  ViewAnalyzing
2SNCASYUA_HUMANS87VEGAG S IAAAT 14.44% HPRD:01227(in vitro)View   
3SNCASYUA_HUMANS87VEGAG S IAAAT 14.44%CK2_group Swiss-Prot 55.0  ViewAnalyzing
4SNCASYUA_HUMANS87VEGAG S IAAAT 14.44% Phospho.ELM 7.0View   
5SNCASYUA_HUMANY125PDNEA Y EMPSE 13.44%LYN HPRD:01227(in vitro;in vivo)  ViewAnalyzing
6SNCASYUA_HUMANY125PDNEA Y EMPSE 13.44%PYK2 HPRD:01227(in vitro;in vivo)  ViewAnalyzing
7SNCASYUA_HUMANY125PDNEA Y EMPSE 13.44%Src Phospho.ELM 7.0  ViewAnalyzing
8SNCASYUA_HUMANY125PDNEA Y EMPSE 13.44%FYN HPRD:01227(in vitro;in vivo)  ViewAnalyzing
9SNCASYUA_HUMANY125PDNEA Y EMPSE 13.44% Swiss-Prot 55.0 View   
10SNCASYUA_HUMANY125PDNEA Y EMPSE 13.44%SYK HPRD:01227(in vitro;in vivo)  ViewAnalyzing
11SNCASYUA_HUMANY125PDNEA Y EMPSE 13.44%Syk Phospho.ELM 7.0  ViewAnalyzing
12SNCASYUA_HUMANY125PDNEA Y EMPSE 13.44%FGR HPRD:01227(in vitro;in vivo)  ViewAnalyzing
13SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%CK2a1 HPRD:01227(in vitro;in vivo)  ViewAnalyzing
14SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%CK2a1(CK2 alpha) Phospho.ELM 7.0 ViewAnalyzing
15SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%BARK1 HPRD:01227(in vitro;in vivo)  ViewAnalyzing
16SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%BARK1(GRK2) Phospho.ELM 7.0 ViewAnalyzing
17SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%GPRK5(GRK5) Swiss-Prot 55.0  ViewAnalyzing
18SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%BARK1 Swiss-Prot 55.0   ViewAnalyzing
19SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%CK2a1-rs HPRD:01227(in vitro;in vivo)  ViewAnalyzing
20SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%CK2a2 HPRD:01227(in vitro;in vivo)  ViewAnalyzing
21SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%CK1a(CK1 alpha) Phospho.ELM 7.0 ViewAnalyzing
22SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%CK1d HPRD:01227(in vitro;in vivo)  ViewAnalyzing
23SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%GPRK5 HPRD:01227(in vitro;in vivo)  ViewAnalyzing
24SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%GPRK5(GRK5) Phospho.ELM 7.0 ViewAnalyzing
25SNCASYUA_HUMANS129AYEMP S EEGYQ 47.14%CK2_group Swiss-Prot 55.0  ViewAnalyzing
26SNCASYUA_HUMANY133PSEEG Y QDYEP 11.07%Syk Phospho.ELM 7.0  ViewAnalyzing
27SNCASYUA_HUMANY136EGYQD Y EPEA 20.18%Syk Phospho.ELM 7.0  ViewAnalyzing
28SNCASYUA_HUMANY136EGYQD Y EPEA 20.18%SYK HPRD:01227(in vitro;in vivo)  ViewAnalyzing